Can Cannabis Treat Sleep Apnea? The Surprising Science Behind THC and Dronabinol
Obstructive sleep apnea (OSA) affects an estimated 30 million Americans, though the majority remain undiagnosed. The condition — characterized by repeated episodes of upper airway collapse during sleep, causing breathing interruptions that can occur hundreds of times per night — is far more than an inconvenience. Untreated OSA increases the risk of hypertension, heart attack, stroke, type 2 diabetes, depression, and cognitive decline. It is, by any measure, a major public health crisis.
The gold standard treatment is continuous positive airway pressure (CPAP), a device that delivers pressurized air through a mask worn during sleep to keep the airway open. CPAP works. The problem is that an alarming number of patients cannot or will not use it. Adherence rates — defined as using the device for at least four hours per night on at least 70% of nights — hover around 50%. Many patients find the masks uncomfortable, claustrophobic, or disruptive to intimacy. They try CPAP, abandon it within months, and return to untreated apnea with all its associated health risks.
This adherence crisis has driven researchers to explore pharmacological alternatives, and one of the most intriguing candidates is a compound most people associate with very different effects: THC.
The Dronabinol Studies
Dronabinol is a synthetic form of THC that has been FDA-approved since 1985 for chemotherapy-induced nausea and AIDS-related appetite loss. Its safety profile is well-characterized, and its legal status as a Schedule III pharmaceutical (even before the broader cannabis reclassification) made it accessible for clinical research.
The investigation into dronabinol for sleep apnea began with a simple observation: the endocannabinoid system plays a role in regulating autonomic respiratory control, particularly the stability of upper airway muscles during sleep. The vagus nerve, which mediates the reflex that keeps the airway open, is modulated by cannabinoid receptors.
The first significant clinical trial was published in 2018 in the journal Sleep. The PACE trial (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) was a Phase II, randomized, double-blind, placebo-controlled study involving 73 adults with moderate to severe OSA. Patients received either placebo, 2.5 mg dronabinol, or 10 mg dronabinol daily for six weeks.
The results were encouraging. The 10 mg dronabinol group showed a statistically significant reduction in the Apnea-Hypopnea Index (AHI) — the primary measure of sleep apnea severity — with a mean reduction of 33% compared to placebo. Patients also reported improvements in subjective sleepiness, as measured by the Epworth Sleepiness Scale. Importantly, dronabinol did not negatively impact sleep architecture as measured by polysomnography — patients were not simply sleeping through apnea events due to sedation but were experiencing genuinely fewer airway obstructions.
Mechanism of Action: How THC Stabilizes the Airway
The mechanism by which THC reduces sleep apnea events is distinct from its better-known psychoactive and analgesic effects. Research has identified several pathways:
Vagal nerve modulation: CB1 receptors on vagal afferent neurons influence the reflexes that control upper airway patency. THC’s activation of these receptors appears to strengthen the tonic activity of the genioglossus muscle — the primary muscle responsible for keeping the tongue from falling backward and blocking the airway during sleep.
Serotonergic interaction: OSA is partly driven by the withdrawal of serotonergic input to upper airway motor neurons during sleep. THC interacts with serotonin signaling pathways in ways that may help maintain this input. Preclinical studies in rats showed that THC applied directly to the nodose ganglion (a cluster of nerve cell bodies on the vagus nerve) reduced apnea events in a dose-dependent manner.
Anti-inflammatory effects: Airway inflammation contributes to OSA by narrowing the upper airway and increasing its collapsibility. THC’s well-documented anti-inflammatory properties — part of the broader cannabinoid modulation of inflammation — may address this contributing factor. The relationship between cannabinoids and inflammation is an area of intensifying research that extends well beyond sleep disorders.
Central respiratory drive: There is emerging evidence that low-dose THC may enhance the sensitivity of central chemoreceptors to CO2, helping the brain respond more quickly to the elevated carbon dioxide levels that occur during apnea events. This could shorten the duration of apneas and reduce the associated oxygen desaturation.
The Phase III Landscape in 2026
Building on the PACE trial results, several larger studies are now underway or recently completed.
The PACE-2 trial, a multi-center Phase III study sponsored by RespireRx Pharmaceuticals, enrolled 360 patients with moderate to severe OSA across 28 clinical sites in the United States and Canada. The trial evaluated 10 mg dronabinol against placebo over 12 weeks, with the primary endpoint being change in AHI. Secondary endpoints included measures of daytime sleepiness, patient-reported quality of life, and cardiovascular biomarkers. Preliminary results presented at the American Thoracic Society meeting in early 2026 showed a mean AHI reduction of 28% — somewhat lower than the Phase II results but still clinically meaningful, particularly for patients who cannot tolerate CPAP.
A separate investigator-initiated trial at the University of Illinois at Chicago is studying dronabinol specifically in patients who have failed CPAP therapy — the population with the most urgent unmet need. This trial is using a higher dose (15 mg) and a longer treatment duration (24 weeks) to determine whether the effects are sustained over time.
Perhaps most intriguingly, a Canadian study is comparing dronabinol head-to-head with CPAP in a non-inferiority design. If dronabinol proves comparably effective to CPAP in a well-powered trial, it would represent a paradigm shift in how sleep apnea is managed.
Beyond Dronabinol: Whole-Plant and Novel Formulations
While dronabinol dominates the clinical trial landscape due to its existing FDA approval and pharmaceutical-grade standardization, researchers are also investigating whether whole-plant cannabis or novel cannabinoid formulations might offer advantages.
A pilot study at the University of Western Australia is evaluating a CBD:THC combination for OSA, based on the hypothesis that CBD’s anxiolytic and muscle-relaxant properties might complement THC’s airway-stabilizing effects. For patients whose sleep apnea is exacerbated by anxiety-driven muscle tension, a combination formulation could theoretically address multiple contributing factors simultaneously.
The involvement of venture capital returning to cannabis biotech has accelerated development of novel delivery systems. At least two startups are developing time-released cannabinoid formulations designed specifically for nighttime use — engineered to maintain stable blood levels throughout the sleep period rather than peaking early and wearing off before morning, when many apnea events occur.
What About Smoking or Vaping Cannabis?
It is critical to distinguish between pharmaceutical-grade dronabinol administered in controlled doses and the recreational use of smoked or vaped cannabis for sleep. Combustion introduces airway irritants and carcinogens that may worsen OSA by increasing upper airway inflammation and edema. Chronic cannabis smoking has been associated with increased upper airway resistance in some studies.
Additionally, the dose-response relationship is narrow. The clinical trials used precisely measured doses of 2.5 to 15 mg of pure THC. A single puff of high-potency cannabis flower could deliver a dose that overshoots the therapeutic window, potentially causing oversedation that masks apnea symptoms without actually reducing events — a dangerous scenario.
For anyone considering cannabis as a sleep aid, tracking consumption and effects through a dedicated cannabis dosing app is strongly recommended, though this should be done in consultation with a sleep specialist rather than as self-medication.
Side Effects and Limitations
Dronabinol is not without side effects. In the clinical trials, the most common adverse events were daytime somnolence (experienced by roughly 15% of participants), dizziness, and cognitive dulling. These effects were generally mild and tended to diminish over the first two weeks of treatment as tolerance developed, but they present a genuine concern for patients who operate heavy machinery or require sharp cognitive performance.
There are also open questions about long-term use. The longest published dronabinol trial for OSA ran 12 weeks. Whether the AHI reduction is maintained over months and years of nightly use, and whether tolerance eventually diminishes the therapeutic effect, are questions that longer-term studies will need to answer.
The drug also does not work for everyone. In the PACE trial, roughly one-third of patients in the active treatment group showed no meaningful AHI improvement. Identifying which patients are likely to respond — perhaps through biomarkers or genetic testing — is an active area of research.
The Regulatory Path Forward
If the Phase III trials produce positive results, dronabinol could receive a new FDA indication for OSA within the next two to three years. The regulatory path is relatively straightforward since the drug already has FDA approval for other indications and decades of safety data.
The Schedule III reclassification of cannabis more broadly has also created a more favorable environment for this research. Researchers report that obtaining DEA licenses, securing institutional review board approvals, and sourcing research-grade material have all become significantly easier — changes that are accelerating timelines across cannabinoid clinical research, including studies on neuroprotective applications.
What Patients Should Know Now
For the millions of sleep apnea patients struggling with CPAP, the dronabinol research offers genuine hope — but it is not yet ready for clinical application outside of trials. The evidence, while promising, has not reached the threshold that would justify recommending dronabinol as a standard treatment. Patients should not self-medicate with cannabis products for sleep apnea.
What patients can do is discuss the emerging research with their sleep specialists, inquire about clinical trial enrollment if they are in a market with an active study site, and ensure that their current treatment plan — whether CPAP, oral appliance therapy, or positional therapy — is optimized.
The path from promising clinical trials to standard of care is never short. But for a condition with a 50% treatment adherence rate, the urgency to develop alternatives is real, and cannabinoid-based therapy may ultimately prove to be part of the answer.